BOULDER, Colo.--(BUSINESS WIRE)--Array BioPharma Inc. (NASDAQ: ARRY) filed an Investigational New Drug (IND) application for ARRY-797 with the U.S. Food & Drug Administration and is now able to proceed with a Phase 1 clinical trial in cancer patients. ARRY-797, a selective, orally active p38 inhibitor, has shown good efficacy and a low side effect profile in preclinical models of certain cytokine-driven cancers. Over the past five months, the compound was evaluated in Phase 1a single ascending dose escalation studies in healthy volunteers for safety, exposure and inhibition of mechanism-related biomarkers.
